MacroGenics (NASDAQ: MGNX) Q4 2024 Earnings Call Mar 20, 2025, 4:30 p.m. ET ...

Parnassus Investments, an investment management company, released the “Parnassus Growth Equity Fund” fourth quarter 2024 ...

Atishay Ltd has secured a significant new work order from The Udaipur Central Cooperative Bank Ltd., Udaipur, Rajasthan.

Servier announces a strategic worldwide licensing agreement for Black Diamond Therapeutics' BDTX-4933 for solid tumors for an ...

We recently published a list of 10 Best Diabetes Stocks To Buy According to Billionaires. In this article, we are going to ...

Q4 2024 Earnings Call Transcript March 17, 2025 FibroGen, Inc. reports earnings inline with expectations. Reported EPS is $-0 ...

Significant progress toward submitting a biologics license application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP) ...

Operator Good afternoon, ladies and gentlemen, and welcome to the INOVIO Pharmaceuticals fourth quarter 2024 financial results conference call. At this time, all lines are in listen-only mode.

Thane Wettig; Interim Chief Executive Officer, Chief Commercial Officer; FibroGen Inc. David Delucia; Vice Presi ...

Doubled the royalty and milestone portfolio to over 120 royalty assets with significant milestone potential through five transactions in 2024 Completed two whole company acquisitions to unlock shareho ...

Reports Q4 revenue $1.99M vs $33.22M last year. “2024 has been an important year for Cellectis (CLLS): we are now developing three programs in ...

H.C. Wainwright & Co. initiates a Buy rating on Perspective Therapeutics, citing promising cancer radiotherapy assets.